China Annual NDA Report Sheds Light On SFDA Thinking, Highlights Pediatric Indications, Orphan Drugs
This article was originally published in The Pink Sheet Daily
China’s State FDA handed out 242 new, and 336 abbreviated new, drug approvals in 2012. Pfizer’s Sutent was one of two products that gained a nod without the need for clinical trials.
You may also be interested in...
Insider Analysis From Easton Associates: Are Patient Assistance Programs The Silver Bullet To Meet Affordability Challenges In China?
Once the world's factory, China has seen costs inch up while drug prices are being cut deeply by centralized procurement schemes. As uncertainties mount, companies need to focus on improving process and scale-up technology, suggested industry observers at a JPM panel discussion on innovation and market access challenges.
The latest figures from China's National Health Commission show infections of the new Wuhan coronavirus are continuing to pile up, spreading to more cities in the country and abroad as travel for the Lunar New Year festival goes into high gear. Meanwhile, diagnostics companies are rushing to have test kits ready.